The Spanish Association of Biosimilar Medicines - BioSim has held a meeting of its Advisory Council, a body made up of various scientific societies, patient associations, health professional associations and professionals of recognized prestige that support the Association's purposes, and that have carried out the balance of the last year and advised on the lines of work for the next year.
In relation to the actions undertaken in 2018, the Association's contribution to improving the training of health professionals in biosimilar medicines was highlighted, through joint work with various scientific societies and professional associations. Likewise, all this for the generation and dissemination of knowledge about biosimilar medicines and the resolution of doubts that professionals may have in daily practice.
The Advisory Council verified the high degree of consensus that exists between health professionals and patients in relation to the values of accessibility, sustainability and efficiency that biosimilar medicines imply within the National Health System, and the decisive contribution that they offer to the improvement of quality of care and increased patient access to innovation.
Lilines of work for 2019.
In relation to the new financial year of 2019, BioSim has considered the reinforcement of various actions and the opening of new activities, among which it stands out to expand its training actions to health professionals and information to patients, in order to increase the levels knowledge about biosimilars. This line of work is a natural continuation of those already carried out in past years towards health professionals and managers, and is aimed at increasing the confidence of all participants in the National Health System in biosimilar medicines.
Along with increasing the scope of training and information actions, BioSim intends to promote measures that place Spain at levels of use of biosimilar medicines comparable to those of our European environment. In this regard, the important progress that has been registered in recent years for biosimilar medicines has been verified, coupled with the appearance of new molecules on the market and the increase in competition in the sector. But, at the same time, it can be seen that there are levels of improvement both in global figures and in the reduction of inequalities in adoption rates. In this sense, the Association intends to maintain the line of work with all health administrations, national and regional, in order to improve the possibilities of use of these drugs.
IN THE PHOTOGRAPHY. From left to right: Ángel Mataix (SEFAP), Francisco Zaragozá, Natacha Bolaños (AGP), Regina Múzquiz (BioSim), Jesús Aguilar (CGCOF), Joaquín Rodrigo (BioSim), Fernando Carballo (FACME), José Luis Andreu (SER) , César A. Rodríguez (SEOM), José Luis Baquero (FEP) and José Luis Gómez Palomares (SEF).
